Lanadelumab is under clinical development by Takeda Pharmaceutical and currently in Phase III for Angioedema. According to GlobalData, Phase III drugs for Angioedema have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lanadelumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lanadelumab overview
Lanadelumab (Takhzyro) recombinant, fully human, monoclonal antibody (IgG1/ κ -light chain) produced in Chinese Hamster Ovary (CHO) cells. It is formulated as injectable solution for subcutaneous route of administration. Takhzyro is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients of 12 years and older.
Lanadelumab (DX-2930, SHP643, TAK-743) is under development for the prophylactic treatment of plasma kallikrein (bradykinin) mediated Hereditary Angioedema (HAE). The therapeutic candidate is administered as subcutaneous and intravenous injection. It is a fully human monoclonal antibody acts by targeting plasma kallikrein.
It was also under development for diabetic macular edema and Coronavirus disease 2019 (COVID-19) pneumonia, factor XII-associated cold autoinflammatory syndrome (FACAS).
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a global pharmaceutical company primarily engaged in the research, development, production, and commercialization of biopharmaceutical products. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. While the company markets its pharmaceutical products directly, it also collaborates with marketing alliance partners in worldwide. Takeda operates in various countries worldwide, including Japan, the US, Europe, Latin America, Africa, the Middle East, and the Asia Pacific region. Takeda is headquartered in Tokyo, Japan.
For a complete picture of Lanadelumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.